Metformin

Generic Name: Metformin

Brand Names: Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₁N_₅

CAS Number: 657-24-9

Unique Ingredient Identifier: 9100L32L2N

Background: Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...

Indication: Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)
...

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate

Associated Therapies: -

Clinical Trials

A Study in Healthy Men to Test Whether BI 1815368 Influences the Amount of Metformin in the Body

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: Metformin hydrochloride
Drug: BI 1815368

First Posted Date: 2024-10-23

Last Posted Date: 2024-11-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT06655220

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity

Phase 4

Recruiting

Conditions: Exercise Capacity
Metformin

Interventions: Drug: Metformin Hydrochloride
Drug: Placebo

First Posted Date: 2024-10-15

Last Posted Date: 2024-12-16

Lead Sponsor: University of Virginia

Target Recruit Count: 20

Registration Number: NCT06638671

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus
Glucotoxicity

Interventions: Drug: Sitagliptin and Gliclazide
Drug: Metformin

First Posted Date: 2024-09-26

Last Posted Date: 2024-09-26

Lead Sponsor: Zhibin Xu

Target Recruit Count: 129

Registration Number: NCT06613750

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Glycemic Regulation As Endometriosis Adjunct Treatment

Phase 2

Not yet recruiting

Conditions: Pelvic Pain
Endometriosis

Interventions: Drug: Placebo
Drug: Metformin Hydrochloride

First Posted Date: 2024-09-25

Last Posted Date: 2024-09-25

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 14

Registration Number: NCT06611501

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome

Phase 3

Recruiting

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Dapagliflozin
Drug: Metformin

First Posted Date: 2024-08-28

Last Posted Date: 2024-10-22

Lead Sponsor: Future University in Egypt

Target Recruit Count: 70

Registration Number: NCT06576375

Locations: 🇪🇬
October 6 University Hospital, Giza, Egypt

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

Phase 3

Recruiting

Conditions: T2DM

Interventions: Drug: CT-L03 Group 1
Drug: CT-L03 Group 2
Drug: Placebo
Drug: Empagliflozin
Drug: Metformin

First Posted Date: 2024-08-26

Last Posted Date: 2024-08-26

Lead Sponsor: Celltrion

Target Recruit Count: 582

Registration Number: NCT06571591

Locations: 🇰🇷
Celltrion, Incheon, Korea, Republic of

Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Cytarabine Injection
Drug: Metformin

First Posted Date: 2024-08-05

Last Posted Date: 2024-08-05

Lead Sponsor: Hospital Municipal São José

Target Recruit Count: 100

Registration Number: NCT06537843

Locations: 🇧🇷
Hospital Ophir Loyola, Belem, Brazil
🇧🇷
Hospital de Clínicas da UFPR, Curitiba, Brazil
🇧🇷
Hospital Amaral Carvalho, Jaú, Brazil

and more 2 locations

Metformin and Vascular Function in Prediabetes

Phase 2

Recruiting

Conditions: PreDiabetes

Interventions: Other: Placebo
Drug: Metformin

First Posted Date: 2024-07-29

Last Posted Date: 2024-11-26

Lead Sponsor: Diana Jalal

Target Recruit Count: 30

Registration Number: NCT06526494

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults

Phase 1

Recruiting

Conditions: Pain

Interventions: Drug: VX-993
Drug: Metformin

First Posted Date: 2024-07-26

Last Posted Date: 2024-10-30

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 32

Registration Number: NCT06523595

Locations: 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States

Safety and Efficacy of Metformin for Treatment of Cytopenia in Children and Adolescents With Fanconi Anemia

Phase 3

Recruiting

Conditions: Fanconi Anemia

Interventions: Drug: Metformin

First Posted Date: 2024-07-25

Last Posted Date: 2024-07-25

Lead Sponsor: Ain Shams University

Target Recruit Count: 30

Registration Number: NCT06519786

Locations: 🇪🇬
Ain Shams University, Cairo, Egypt
🇪🇬
University of Alexandria, Alexandria, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy